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ABSTRACT 
Neuregulin-1 (NRG1) signaling through tyrosine kinase receptors erbB2 and erbB4 was 
revealed essential for cardiac development as mouse mutated in the Nrg1 or either cognate 
receptors Erbb2 or Erbb4 genes lack the formation of trabeculae at the ventricular wall. 
Indeed, the injection of the NRG1 active peptide in developing embryos induced trabeculation 
of the ventricular free wall. The components of the NRG1 pathway have been identified and 
the cardiac activities are being progressively characterized. An acquired form of dilated 
cardiomyopathy was evidenced in a subpopulation of breast tumor patients undergoing a 
combined treatment with antibodies against erbB2 and chemotherapy. In this regard, the 
cardiomyocyte-specific gene deletion of either erbb2 or erbb4 leads to ventricular dilation in 
adult mice, providing an experimental model system to examine the NRG1-mediated 
activities. We reviewed the evidence on the growing field of research for NRG1 signaling in 
both cardiac morphogenesis and in the postnatal myocardial remodeling. 
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INTRODUCTION 
 
The Neuregulin pathway 
 
The neuregulins are transmembrane proteins of four isotypes (NRG1-4), which active domain 
is related to the epidermal growth factor (EGF). The NRG1 is classified into three subgroups 
(I–III), which includes about 30 isoforms as the result of the expression from different 
promoters and of splicing variants encoded in over 1.2 Mb, one of the largest genes in the 
mammalian genome [1]. The active amino terminal domain of the type I and II is released by 
metalloproteinase (ADAM 17, 19), modulated by PKC-delta and cleaved by α-secretase 
activity [2, 3]. The extracellular active domain of type III NRG1 remains attached to the 
transmembrane domain, which is therefore suggested to signal in the immediate environment 
(Figure 1A). The NRGs activate the tyrosine kinase receptors, erbB2, erbB3 and erbB4 that 
belong to the EGF receptor family (erbB1) [4]. The neuregulin and erbB2 were first identified 
in unrelated research topics of the neuromuscular junction and cancer cells respectively, and it 
had been ten years later, in 1993, that these molecules were characterized as the ligand and co-
receptor of the same signaling pathway. 
 
The NRG1-erbB signaling activities in cardiac development 
 
In the heart, the type I and II of NRG1 are expressed in endocardial cells of the endocardium 
which are subjected to proteolytic cleavage (Figure 1A). The released active peptides of the 
NRG1β isoform bind and activate erbB2/erbB4 heterodimers, expressed in cardiomyocytes 
(Figure 1B). 
In the late 1995, the phenotype of genetically recombined Nrg1 or either Erbb2 and Erbb4 
genes in mouse revealed the critical activities of this pathway for embryonic development, 
which embryos died in utero at E10.5 days post coitum (dpc) [5-7].  The developing heart of 
these 3 lines of gene knockout mice had impaired or nil formation of the trabeculae at the 
ventricular free wall. Trabeculae are a network of cardiomyocytes growing into the chamber 
lumen that contribute to the thickening of the myocardium and to the formation of the 
ventricular conduction system.  The first evidence for the role of NRG1 in the developing 
heart prompted the study of the pathway activities in experimental model systems.  In an ex-
vivo developing embryo culture system, the cardiac injection of NRG1β and α active peptides 
(70 aminoacids) was sufficient to induce trabeculation of the ventricular wall (Figure 1C), 
which stronger activity was displayed by the β relative to the α isoform [8]. 
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Figure 1. A) Schematic representation of type I, II, III NRG1. Although not expressed in the heart, type III was 
included for graphic purpose. B) NRG1 binding and activation of erbB receptors. C) Formation of Trabeculae by 
NRG1 through erbB2/erbB4 activation. 
 
 
In addition to the NRG1-mediated differentiation and specification of cardiomyocytes into 
trabeculae, NRG1 was found to induce cardiomyocytes to proliferate at the compact zone of 
the ventricular wall when co-injected with IGF-I peptides. These results suggest that growth 
factor activities may interact by modulating the dominant individual effects and indicate that 
NRG1/IGF-I induce differentiation in proliferating cardiomyocytes, forming trabeculae [8]. 
Experiments carried out in zebrafish indicate that the NRG1-induced trabeculation is mediated 
by proliferation followed by the directional migration of differentiating cardiomyocytes, as 
opposed to a directional budding of proliferative cardiomyocytes into the chamber lumen [9]. 
Recent experiments employing homozygous mice for hypomorphic Nrg1 alleles, which lack 
the transmembrane domain, demonstrated that the central outermost part of the left ventricle 
was the most affected region as monitored by the early inactivation of gene expression at E8.5 
dpc.  This result indicates a role for NRG1 beyond the formation of trabeculae, in 
cardiomyocytes of the compact zone, potentially linking biochemical feedback to molecular 
pathways for growth and differentiation, acting on the central part of the ventricular wall that 
sustains contraction [10]. In this scenario, the NRG1 pathway displays morphogenetic 
activities on diverse cardiac tissues. The erbB receptors are involved in cushion 
morphogenesis, which is initiated by epithelial-mesenchyme transformation giving rise to the 
prospective valves.  Indeed, a murine model of defective valve formation by hyaluronan gene 
inactivation was rescued by the administration of NRG1 with the concomitant phosphorylation 
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of erbB2 and erbB3. These results associate the NRG1 pathway to valve formation through 
mesenchyme-extracellular matrix interactions [11]. 
The septation and maturation of the outflow tract depends on erbB4-positive cardiomyocytes 
and erbB3-positive neural crest cells that migrate to the lateral mesenchyme of the dorsal aorta 
in mice. A congenital form of left ventricular outflow tract defects was positively associated 
with a specific haplotype in the ERBB4 gene [12].  Recently, certain polymorphisms in ERBB2 
[13] and in the NRG1 [14] genes have been suggested to be biologically significant in the 
pathogenesis of nonneoplastic disease, such as schizophrenia or cardiovascular disorders.  
Thus far, further experimentation is required to directly address the specific functions of ErbB 
and NRG1 isoforms in disease. 
Altogether, it is suggested that NRG1 orchestrates gene expression in a feedback modulation 
with wall stress, contractility and blood flow parameters, acting on the coordinated growth of 
the cardiac chambers during morphogenesis. 
 
The NRG1 intracellular signaling cascade.  
 
The erbB-dependent intracellular cascades have been extensively studied because of the 
important role in cancer cells, thereby, providing the basis for the analyses of signaling 
mechanisms in other cell types. The NRG activation of erbB receptors mediates auto- and 
trans-phosphorylation of tyrosine residues at the receptor intracellular domain. A subgroup of 
phosphotyrosine residues bind specific adaptor molecules (e.g. Grb, Shc, Src, SH3 domain) 
[13], ultimately inducing intracellular pathways, e.g. MAP kinase, and PI 3´-kinase cascades, 
PLC γ, the regulation of the Ca2+-dependent Protein Kinase C and NFAT activity (Figure 2) 
[4]. A link between NRG1 and focal adhesion kinase (FAK) has been found in proliferative 
and migrating cells.  
In cultured cardiomyocytes, the Ras/MAPK/erk1/2 pathway was required for the NRG1-
driven myofibrillogenesis in cultured cardiomyocytes. This activity was mimicked by a 
constitutively active form of Ras and inhibited by its dominant negative form and by the 
MEK1 inhibitor PD98059 [8].  The induced ability of cardiomyocytes to proliferate was 
dependent on NRG1/IGF-I through the activation of the PI 3´-kinase/Akt pathway, which was 
verified by the wortmannin inhibition of cardiomyocyte DNA synthesis in embryonic 
development and in cultured neonatal cardiomyocytes.  The cellular transfection with 
adenovirus harboring a constitutively active Akt mimicked the proliferative and protective 
activities, which were inhibited by a dominant negative form of Akt in the presence of 
NRG1/IGF-I [8].  
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Figure 2. Schematic representation of NRG1-erbB2/erbB4 intracellular signaling 
 
ErbB non-phosphorylated interactions.  
 
Intracellular signaling also depends on the binding ability of specific non-phosphorylated 
residues at the C-terminal domain of erbB receptors to PDZ domain containing proteins. This 
protein domain was named by homology to the interacting region of the Post synaptic protein 
95, Disc large and Zona occludens ZO-1 proteins with four highly conserved residues GLGF. 
The interaction to PDZ domain proteins is relevant for the specific location of erbB proteins 
into particular membrane compartments and for the modulation of the receptor stability and 
activity [14]. Despite the significance of PDZ domain proteins in the heart (e.g. MAGUK, 
actinin binding proteins), there is not yet evidence for the specific PDZ-erbB-interacting 
proteins in cardiomyocytes. The erbB4 receptors, which are endocytosis-impaired, are also 
regulated through proteolysis mediated by the proteasome system and by the alternative 
transcriptional activity of the cleavable juxtamembrane isoform JMa. These mechanisms 
either drive the erbB4 protein degradation or induce the nuclear translocation of the JMa 
intracellular domain. As it occurs for the release of the NRG1 active peptides, the release of 
the erbB4 JMa C-terminal domain is modulated by the activation of PKC and mediated via the 
activity of tumor necrosis factor-alpha converting enzyme and further cleavage by γ-secretase 
at the plasma membrane. In the heart, the identified erbB4 protein in cardiomyocytes is the 
JMb non-cleavable splice variant which may be proteolyticaly modulated by the proteasome 
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system [15]. Three PPXY motifs couple erbB4 with WW domain proteins, such as Wwox and 
ubiquitin ligases, modulating the activity of the c-terminal domain[16]. 
 
The requirement of erbB in the adulthood. 
 
The clinical impact of the NRG1 signaling in cardiology was the increased incidence of 
dilated cardiomyopathies in a subpopulation of breast tumor patients undergoing the combined 
administration of anthracycline chemotherapy and a humanized antibody against erbB2 
protein (trastuzumab, pertuzumab) [19]. The cardiac effect of these humanized antibodies, 
which are species specific and do not cross-react with the mouse protein, was experimentally 
assessed through the ventricular cardiomyocyte-specific-deletion of either Erbb2 or Erbb4 in 
mouse. The tissue-specific mutation in any of these genes in mouse led to dilated 
cardiomyopathy in the adulthood (Figure 3) [20, 21]. These murine models were useful to 
demonstrate the cardiomyocyte-autonomous and essential requirement of the erbB2/erbB4 
during the postnatal remodeling of the myocardium.   
 
 
 
 
Figure 3. Ventricular specific erbB4-KO leads to adult dilated cardiomyopathy. 
 
Subcellular localization of erbB2/erbB4.  
 
Clues about a local cardiomyocyte effect of NRG1 for the maintenance of myocardial 
architecture arise from the subcellular localization of the receptors.  The erbB2/erbB4 proteins 
were found accumulated in the T-tubule membrane system of cardiomyocytes and in the 
intercalated discs (ID) [21] (Figure 4) 
The relevance of the receptor localization is that the T-tubules place membrane molecules in 
close apposition of the myofibril Z-disc, providing a specific context for the functional 
interactions among molecules at the plasma membrane, sarcoplasmic reticulum (SR) and the 
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myofibril Z-disc. The ID are highly specialized Z-disc structures at the cell-cell contacts that 
provide the anchorage of the sarcomeres to the membrane and placed the connexin-43 gap 
junctions, assuring electric transmission and the rhythmic contraction of cardiomyocytes of the 
ventricular chamber. 
The erbB subcellular context suggests that NRG1 may act on intersecting cues to cytoskeletal 
pathways required for myocardial remodeling. A connection of NRG1 signaling with the 
cytoskeleton has been also suggested during cardiac morphogenesis in a feedback modulation 
with changes in wall stress and contractile parameters. 
 
 
Figure 4. Endothelium-Cardiac muscle interactions through paracrine NRG1 signaling. Functional interaction of 
molecules placed at the T-tubules, SR, Z-band, ID and costameres. 
 
Cardioprotective and regenerative activities. 
 
In agreement with the requirement of the NRG1-erbB2/erbB4 pathway for the prevention of 
ventricular dilation during remodeling, NRG-1/erbB2 signaling has been shown to be critical 
for the physiologic cardiac hypertrophy manifested during pregnancy in rodents.  Accordingly, 
the lapatinib-mediated inhibition of erbB2 phosphorylation resulted in a pathologic pregnancy-
related dilation of the ventricular chambers that occurs without apparent apoptotic cell death 
[22]. Downregulation of erbB2 and erbB4 expression was evidenced during the pathologic 
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remodeling of the myocardium in rodents under pressure overload and in humans with a 
failing myocardium [23]. 
The in vivo administration of NRG1 in different conditions of mouse cardiac pathology 
contributed to the amelioration of contraction (reduced left ventricular end systolic 
dimensions, increased ejection fraction). In these experiments, the NRG1-mediated functional 
performance of the ventricular chambers was correlated with the increased phosphorylation of 
the myosin regulatory light chain (RLC) [24]. However, the administration of NRG1 in 
knockout mouse for the myosin light chain kinase, Mlck, gene improves cardiac performance 
without an increase in the phosphorylation level of RLC [25], implicating additional 
mechanisms for the contractile improvement. In cultured cardiomyocytes, NRG1 appears to 
exert a negative inotropic effect through either NOS activity [26] or via the activation of the 
muscarinic response [27]. Both NO production and active muscarinic receptors modulate the 
inotropic response to beta-adrenergic stimulation, which may result in an improved fractional 
shortening. Indeed, there is a general lack of evidence of a direct inotropic effect, or induced 
changes in calcium handling or in myofilament calcium sensitivity that may explain the 
NRG1-mediated enhancement in the cardiac systolic function.   
Additional repair activities have been suggested in a murine model of cardiac infarction.  In 
this setting, the exogenous administration of NRG1 was shown to induce mononucleated 
cardiomyocytes to proliferate contributing to cardiac repair mechanisms, without affecting the 
level of apoptotic cell death [28].  
In cultured cardiomyocytes, NRG1 appeared to protect doxorubicin-mediated myofibril 
disarray [29], and the toxic degradation of the troponins [30]. These results are in line with the 
beneficial cardiac effect of NRG1 in one week old myocardial infarction [28].  
The cardioprotective activity of NRG1 was also inferred by the doxorubicin-aggravated 
contractile dysfunction in heterozygous NRG1 mutant mice [31] and the exacerbated 
ventricular dilation in erbB4-KO [32]. The administration of doxorubicin to erbB4-KO mice 
led to the downregulation of components of the IGF-I pathway accompanied by deregulation 
of the ubiquitin-proteasome system [32]. The mechanisms leading to cardiomyocyte death by 
autophagic vacuolization and necrosis were synergistically induced in the doxorubicin-treated 
erbB4-KO heart. The relevance of protein-ubiquination was documented for autophagic 
vacuolization as a useful predictor of myocardial deterioration [33]. Moreover, the monitoring 
of necrotic cardiomyocytes by the determination of cTnI serum level is a highly sensitive 
cardiotoxic marker for breast tumor patients following trastuzumab and doxorubicin therapy 
[34]. 
 
Conclusions 
 
The relevance of the NRG1-erbB2/erbB4 pathway in the heart was characterized by the 
induced formation of trabeculae at the ventricular free wall during embryonic development, 
promoting differentiation in proliferative cardiomyocytes. The embryonic activities of NRG1 
signaling appeared to be also required beyond the formation of trabeculae, acting on the 
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regulation of gene expression in cardiomyocytes of the central part of the ventricular wall, 
which is critical for pressure development. The NRG1-erbB2/erbB4 pathway is critical for the 
maintenance of the myocardial structure in the adult heart, and moreover, an impaired NRG1 
signaling exacerbates the anthracycline-mediated cardiotoxicity. The accumulated data 
indicates a panel of NRG1-dependent protective and repair activities displayed in the heart 
during the lifespan of the individuals, which molecular events remain unclear. There are 
central questions about the NRG1/erbB biology to be addressed as to how NRG1 affects 
cytoskeletal pathways during cardiac remodeling.   
The continuous research in this area will provide the critical molecules and targets which may 
help the design of diagnostic tools and therapeutic strategies, particularly relevant for patients 
with erbB2-positive breast tumors undergoing the combined treatment with anthracyclines and 
trastuzumab. 
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